Diagnostic Kits/Page for Joint Creation of Blog Post

From Commons Based Research
< Diagnostic Kits
Revision as of 12:47, 16 October 2009 by AClearwater (talk | contribs) (added Richard Nelson)
Jump to navigation Jump to search

Blog Post

  • Introduction to Our Research
    • The field of Biotechnology including Genomics and Proteomics is a critical US industry. The emerging research in the genetic diagnostic kits presents unique challenges in intellectual property (IP). Changes in laboratory research due to actual or anticipated patent or license enforcement could signal the failure of intellectual property to spur the innovation these protections are intended to promote. It is these issues that are at the centre of our research under the Industrial Cooperation Project at the Berkman Centre at Harvard University. This research is part of a broader project being led by Prof. Yochai Benkler. In the research, we are seeking to understand the approaches to innovation with genetic diagnostic kits looking specifically at barriers to use and innovation.
  • 2 paragraphs on the field and our focus (Mac)
  • Relevent Caselaw
    • The most important legal protections of genetic diagnostic kits are trade secret and patents. While trade secret plays a large role, studying it is difficult because most of the information is not public. Patents are public information and they have been the focus of our current research. The gene-disease associations that researchers study can be developed into a genetic diagnostic kit and these tests are often covered by patents. Our research aims to discover the role patents play in genetic diagnostic kit development and commercialization. The Bilski case “machine-or-transformation” test provides patent protection for genetic diagnostic kits if the machine or transformation used in the claimed process would "not merely be insignificant extra-solution activity." In re Bilski, 545 F.3d 943, 962 (Fed. Cir. 2008) (en banc), cert. granted, 129 S. Ct. 2735 (2009). The recent Prometheus Labs case investigate the bounds of the Bilski case by looking specifically at a transformation that takes place within the human body. Prometheus Labs., Inc. v. Mayo Collaborative Servs., No. 2008-1403, slip op. at 8 (Fed. Cir. Sept. 16, 2009).[[1]] This broad interpretation of a transformation has important implications about the scope of protection that genetic diagnostic kits will receive. The finality of this analysis will be determined when the Supreme Court reviews Bilski.
  • Influential Discussions

"The market economy, and the scientific commons" Richard R. Nelson On of the dangers present in the patent protections surrounding genetic diagnostic tests is that basic scientific knowledge is being protected.

  • The Role of Universities
    • Research universities are active in DNA patenting and licensing so technology transfer is central to how important developments in diagnostic tests are licensed. Patenting or research is encouraged by the Bayh-Dole Act which deals specifically with federal government-funded research but has more widely effected the patenting procedure of all university research. If a university elects to hold title to the federally funded invention it is obligated to patent and attempt to commercialize the invention. A theoretical limit on this a set of "march in rights" held by the funding agency which would allow it to grant further licenses but this right is constrained by a necessity analysis under the statute and until now the rights have only been requested or threatened but never used. Another source of licensing restriction can come from the source fo the funds. For instance, the National Institutes of Health is a major source of funding and their funding power has allowed them to create guidelines on how to license research resources arising from the funded research.

Check https://cbr-diagnostics.etherpad.com/1 for current progress & collab editing

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/Page_for_Joint_Creation_of_Blog_Post&oldid=4599"